ABSTRACT
Chorea-acanthocytosis and McLeod syndrome are the core diseases among the group of rare neurodegenerative disorders called neuroacanthocytosis syndrome (NAS). NAS patients have irregularly spiky erythrocytes, so-called acanthocytes. Their detection is a crucial but error-prone parameter in the diagnosis of NAS, often leading to misdiagnosis. Based on the standard Westergren method, we show that the acanthocyte sedimentation rate (ASR) with a two-hour read-out is significantly prolonged in Chorea-acanthocytosis and McLeod syndrome without overlap compared to the erythrocyte sedimentation rate (ESR) of controls. Thus, the ASR/ESR is a clear, robust and easily obtained diagnostic marker. Mechanistically, through modern colloidal physics, we show that acanthocyte aggregation and plasma fibrinogen levels slow down the sedimentation. This study is also a hallmark of the physical view of the erythrocyte sedimentation by describing anticoagulated blood in stasis as a percolating gel, allowing the application of colloidal physics theory.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Deutsche Forschungsgemeinschaft (DFG) in the framework of the research unit FOR 2688 "Instabilities, Bifurcations and Migration in Pulsatile Flows", by the European Union Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 860436 - EVIDENCE and by the Saarland University competitive funding (Forchungsausschuss). K.P. was supported by the Else Kroener Clinician Scientist Program (TU Dresden, Germany) and the Rostock Academy for Clinician Scientists (RACS, University of Rostock, Germany), A.H. is supported by the "Hermann und Lilly Schilling-Stiftung fuer medizinische Forschung im Stifterverband". F.Y., T.J. and C.W. acknowledge funding from French German University (DFH / UFA). We are indebted to the Advocacy for Neuroacanthocytosis Patients (www.naadvocacy.org) for financial support for chorea Western blotting. We also gratefully acknowledge the computing time granted through JARA-HPC on the supercomputer JURECA at Forschungszentrum Juelich. We would like to thank Alexander Kihm and Dr. Hannes Glass for help in obtaining blood samples, their handling and transportation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval for this research was provided by the "Ethikkommission bei der Aerztekammer des Saarlandes" (Ethical Committee of the Saarland Medical Chamber).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The title has been clarified, the abstract was shortened and the Material and Methods has been reorganized for clarity purposes. The layout has been formatted in accordance to eLife specifications, in order to ask for a review of the preprint version, if possible.
Data Availability
Most of the data generated and/or analyzed during this study are present in the paper or the Supplementary Figures. Intermediate technical results or newly design analyses software is available upon reasonable request to the corresponding authors.
